Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearPoint Neuro, Inc.MRIC · Entity 2367 | Director | May 17, 2019 | May 17, 2019 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Chief Operating Officer | February 10, 2020 | February 12, 2020 |
| Praxis Precision Medicines, Inc.PRAX · Entity 3538 | Director · Chief Executive Officer | July 08, 2026 | July 08, 2026 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | August 25, 2022 | August 25, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearPoint Neuro, Inc.
Report date May 17, 2019 · Filed May 17, 2019
This filing explicitly reported no securities owned.
PTC THERAPEUTICS, INC.
Report date February 10, 2020 · Filed February 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 7,369 |
Reported balance
After 2020-02-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-02-10 · Exercise / conversion · Acquired 625 · Balance 7,369 F1: Transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted on November 19, 2019. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 6,744 |
Reported balance
After 2020-02-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-02-10 · Sale · Disposed 625 · Balance 6,744 F1: Transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted on November 19, 2019. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.92 · Expires 2027-05-17 | IndirectBy Spouse | 3,125 |
Reported balance
After 2020-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-10 · Exercise / conversion · Disposed 625 · Balance 3,125 F1: Transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted on November 19, 2019. F2: This option was granted on May 17, 2017, and vests over four years, with 25% of the shares underlying the option vesting on May 8, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on August 8, 2018. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.01 · Expires 2028-01-02 | IndirectBy Spouse | 2,696 |
Reported balance
Holding disclosure · report date 2020-02-10 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 2,696 F3: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.02 · Expires 2029-01-21 | IndirectBy Spouse | 6,825 |
Reported balance
Holding disclosure · report date 2020-02-10 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 6,825 F4: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.16 · Expires 2030-01-28 | IndirectBy Spouse | 4,170 |
Reported balance
Holding disclosure · report date 2020-02-10 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 4,170 F5: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted on November 19, 2019.
F2: This option was granted on May 17, 2017, and vests over four years, with 25% of the shares underlying the option vesting on May 8, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on August 8, 2018.
F3: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
F4: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
F5: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
Praxis Precision Medicines, Inc.
Report date July 08, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,495 |
Reported balance
After 2026-07-08 transaction · row 1
1 source rowRow 1 · 2026-07-08 · Gift · Disposed 20,521 · Balance 56,495 F1: This transaction represents a bona fide gift of common stock to the Souza 2026 Trust. |
| Common StockSEC Table I · non-derivative | IndirectHeld by spouse | 0 |
Reported balance
After 2026-07-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-08 · Gift · Disposed 2,600 · Balance 0 F1: This transaction represents a bona fide gift of common stock to the Souza 2026 Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents a bona fide gift of common stock to the Souza 2026 Trust.
Spyre Therapeutics, Inc.
Report date August 25, 2022 · Filed August 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 90,000 |
Reported balance
After 2022-08-25 transaction · row 1
1 source rowRow 1 · 2022-08-25 · Purchase · Acquired 90,000 · Balance 90,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 30,000 | $18.01 Strike: $18.01 | $540,300.00 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · derivative · entry 16 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 30,000 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. F13 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 15,881 | $11.23 Strike: $11.23 | $178,343.63 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · derivative · entry 15 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,219 Underlying: Common Stock · 15,881 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. F12 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 30,000 | $12.53 Strike: $12.53 | $375,900.00 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · derivative · entry 14 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2027-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. F11 · derivative.exercise_date: Currently exerciseable. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,250 | $48.80 | $305,000.00 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 13 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 5,038 F10 · kind: The transactions of the Reporting Person's spouse reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on November 19, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 6,250 | $12.92 | $80,750.00 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 12 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 11,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · kind: The transactions of the Reporting Person's spouse reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on November 19, 2019. F3 · balance_after: Includes 371 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 18,668 | $49.19 | $918,278.92 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 11 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,221 F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.82 to $49.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 11,332 | $48.43 | $548,820.09 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 10 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,889 F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.82 to $48.82 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 30,000 | $18.01 | $540,300.00 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 9 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,004 | $49.32 | $345,430.28 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 8 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,221 F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $49.03 to $49.65 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 8,877 | $48.58 | $431,244.66 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 7 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,225 F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.02 to $49.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 15,881 | $11.23 | $178,343.63 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 6 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 21,271 | $49.14 | $1,045,256.94 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 5 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,221 F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.77 to $49.65 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 8,729 | $48.32 | $421,794.01 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 4 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,492 F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.77 to $48.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 30,000 | $12.53 | $375,900.00 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 3 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 14,814 | $49.14 | $727,974.77 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 2 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,221 F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.77 to $49.65 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,000 | $48.32 | $289,932.00 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,035 F1 · kind: The Reporting Person's transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2019. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.75 to $48.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 371 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2019. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 01:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,490 | $40.38 | $221,686.20 |
DisclosureSEC source: 0001070081-19-000036 · wf-form4_155969696332378.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,664 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 15,000 shares of restricted stock from a May 31, 2017 grant of 30,000 shares. F2 · balance_after: Includes 715 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2018 and 368 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2018. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:45 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 6,825 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001104659-19-003196 · a4.xml · derivative · entry 4 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 6,825 Underlying: Common Stock · 6,825 shares Expires 2029-01-21 F2 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:45 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001104659-19-003196 · a4.xml · derivative · entry 3 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-01-21 F3 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:45 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001104659-19-003196 · a4.xml · derivative · entry 2 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2029-01-21 F2 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:45 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-003196 · a4.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 4,667 F1 · shares: Restricted stock unit granted on January 22, 2019 that vests in four equal installments over four years, commencing on January 22, 2020. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 22:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 83 | $34.75 | $2,884.25 |
DisclosureSEC source: 0001070081-19-000011 · wf-form4_154707195442272.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,742 F1 · kind: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 269 RSUs from a January 3, 2018 grant of 1,079 RSUs. F2 · balance_after: Includes 715 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2018 and 368 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2018. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:22 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,161 | $34.65 | $178,828.65 |
DisclosureSEC source: 0001070081-18-000052 · wf-form4_152814373741541.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,071 F1 · kind: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 15,000 shares of restricted stock from a May 31, 2017 grant of 30,000 shares. F2 · balance_after: Includes 1,112 shares acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2017 and 663 shares acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2017. Includes 30,000 shares of a restricted stock award awarded to the Reporting Person on May 31, 2017 and reported on the Form 4 filed by the Reporting Person on June 2, 2017, which shares were inadvertently not previously included in Column 5 of Table 1 on such Form 4. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 2,696 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001070081-18-000017 · wf-form4_151518647228588.xml · derivative · entry 3 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,696 Underlying: Common Stock · 2,696 shares Expires 2028-01-02 F3 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 75,000 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001070081-18-000017 · wf-form4_151518647228588.xml · derivative · entry 2 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-01-02 F3 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-18-000017 · wf-form4_151518647228588.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,742 F1 · shares: Restricted stock unit (RSU) award vests in four equal annual installments over four years, commencing on January 3, 2019. Upon vesting, each RSU will convert into one share of the issuer. F2 · balance_after: Includes 663 shares acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2017. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 22:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 30,000 | $12.53 Strike: $12.53 | $375,900.00 |
DisclosureSEC source: 0001070081-17-000096 · wf-form4_149644405900854.xml · derivative · entry 2 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2017-05-31 F2 · derivative.exercise_date: This option was granted on May 31, 2017, and vests in two equal annual installments over two years, commencing on May 31, 2018. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 22:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-17-000096 · wf-form4_149644405900854.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,457 F1 · shares: Restricted stock awarded to the Reporting Person vests in two equal annual installments over two years, commencing on May 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.